Abstract

Research Article

Impact of the COVID-19 infection on the “benign” nature of the illness of Schönlein-Henoch

A Vasileva*, IV Chakarov and P Chakarova

Published: 11 January, 2022 | Volume 6 - Issue 1 | Pages: 007-010

The incidence of COVID-19 in children has been variable. Although now the number of infected children worldwide, and in particular nationally, is small, they are not protected from the infection. Moreover, in the most severe cases septic shock, metabolic acidosis, irreversible bleeding, and coagulation dysfunction have been registered.
In February 2021 a 17-year-old boy showed for examination with complaints of pain in the upper part of the abdomen, accompanied by involvement of the ankle joints, the appearance of a rash on the lower extremities with the characteristic of hemorrhagic vasculitis, and a positive test for COVID-19. The characteristics of the skin purpura, the abdominal pain, and the arthralgia led us to the diagnosis of Schönlein-Henoch purpura. 
The verification of past COVID-19 infection was done by the established high titer of specific IgG antibodies. The clinical evolution of the disease went beyond its generally accepted benign nature - the first manifestation of the illness had been followed by four more relapses, which necessitated new hospitalizations and a change in the therapeutic approach.
COVID-19 infection is the cause of a more aggressive course of vasculitis.

Read Full Article HTML DOI: 10.29328/journal.ijcv.1001042 Cite this Article Read Full Article PDF

Keywords:

COVID-19; Henoch-Schönlein purpura; Abdominal pain

References

  1. Shi JS, Gu JY, Wang M. Clinical manifestations, gastroscopic, and pathological features of abdominal type Henoch-Schonlein purpura in children. Pediatr Nephrol. 2013; 28: 1424-1424.
  2. Hung SP, Yang YH, Lin YT, Wang LC, Lee JH, et al. Clinical manifestations and outcomes of Henoch-Schönlein purpura: comparison between adults and children. Pediatr Neonatol. 2009; 50: 162-168. PubMed: https://pubmed.ncbi.nlm.nih.gov/19750891/
  3. Mills JA, Michel BA, Bloch DA, Calabrese LH, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. Arthritis Rheum. 1990; 33: 1114-21. PubMed: https://pubmed.ncbi.nlm.nih.gov/2202310/
  4. Davies PJ. Mozart’s death: a rebuttal of Karhausen: further evidence for Schönlein-Henoch syndrome. J R Soc Med. 1991; 84: 737-740. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1295524/
  5. Couture A, Veyrac C, Baud C, Galifer RB, Armelin I. Evaluation of abdominal pain in Henoch-Schönlein syndrome by high frequency ultrasound. Pediatr Radiol. 1992; 22: 12-17. PubMed: https://pubmed.ncbi.nlm.nih.gov/1594303/
  6. Martinez-Frontanilla LA, Haase GM, Ernster JA, Bailey WC. Surgical complications in Henoch-Schönlein Purpura. J Pedaitr Surg. 1984; 19: 434-436. PubMed: https://pubmed.ncbi.nlm.nih.gov/6481588/
  7. Besbas N, Saatci U, Ruacan S, Ozen S, Sungur A, et al. The role of cytokines in Henoch-Schonlein purpura. Scand J Rheumatol. 1997; 26: 456-460. PubMed: https://pubmed.ncbi.nlm.nih.gov/9433407/
  8. Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol. 2010; 22: 598-602. PubMed: https://pubmed.ncbi.nlm.nih.gov/20473173/
  9. Del Vecchio GC, Penza R, Altomare M, Picante L, Aceto G, et al. Cytokine pattern and endothelium damage markers in Henoch-Schönlein purpura. Immunopharmacol Immunotoxicol. 2008; 30: 623-629. PubMed: https://pubmed.ncbi.nlm.nih.gov/18668398/
  10. Dalens B, Travade P, Labbé A, Bezou MJ. Diagnostic and prognostic value of fibrin stabilising factor in Schönlein-Henoch syndrome. Arch Dis Child. 1983; 58: 12-14. PubMed: https://pubmed.ncbi.nlm.nih.gov/6830268/
  11. Kamitsuji H, Tani K, Yasui M, Taniguchi A, Taira K, et al. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schönlein purpura. Efficacy of factor XIII substitution. Eur J Pediatr. 1987; 146: 519-523. PubMed: https://pubmed.ncbi.nlm.nih.gov/3678279/
  12. Bowyer SL, Ragsdale CG, Sullivan DB. Factor VIII related antigen and childhood rheumatic disease. J Rheumatol. 1989; 16: 1093-1097. PubMed: https://pubmed.ncbi.nlm.nih.gov/2585406/
  13. Nusinow SR, Federici AB, Zimmerman TS, Curd JG. Increased von Willebrand factor antigen in the plasma of patients with vasculitis. Arthritis Rheum. 1984; 27: 1405-1410. PubMed: https://pubmed.ncbi.nlm.nih.gov/6508862/
  14. Woolf AD, Wakerley G, Wallington TB, Scott DGI, Dieppe PA. Factor VIII related antigen in the assessment of vasculitis. Ann Rheum Dis. 1987; 46: 441-447. PubMed: https://pubmed.ncbi.nlm.nih.gov/3115202/
  15. Vasavada P. Ultrasound evaluation of acute abdominal emergencies in infants and children. Radiol Clin North Am. 2004; 42: 445-456. PubMed: https://pubmed.ncbi.nlm.nih.gov/15136027/
  16. Ozdemir H, Isik S, Buyan N. Sonographic demonstration of intestinal involvement in Henoch-Schönlein syndrome. Eur J Radiol. 1995; 20: 32-34. PubMed: https://pubmed.ncbi.nlm.nih.gov/7556249/
  17. Bomelburg T, Claasen U, von Langerke HJ. Intestinal ultrasonographic findings in Schönlein-Henoch syndrome. Eur Pediatr. 1991; 150: 158-160. PubMed: https://pubmed.ncbi.nlm.nih.gov/2044583/
  18. Yang HR, Choi WJ, Ko JS, Seo JK. Intravenous immunoglobulin for severe gastrointestinal manifestation of Henoch-Schönlein purpura refractory to corticosteroid therapy. Korean Pediatr. 2006; 69: 798-806. PubMed: https://pubmed.ncbi.nlm.nih.gov/27133370/
  19. Ebert EC. Gastrointestinal manifestations of Henoch-Schonlein purpura. Dig Dis Sci. 2008; 53: 2011-2019. PubMed: https://pubmed.ncbi.nlm.nih.gov/18351468/
  20. Fukui H, Kamitsuji H, Nagao T, Yamada K, Akatsuka J, et al. Clinical evaluation of a pasteurizes factor XIII concentrate administration in Henoch-Schönlein purpura. Thromb Res 1989; 56: 447-75.

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More